Zimmer Biomet price target lowered to $104 from $118 at Citi

Citi lowered the firm’s price target on Zimmer Biomet (ZBH) to $104 from $118 and keeps a Neutral rating on the shares. The company delivered better-than-expected Q1 results, hurdling one fewer selling day, with revenue slightly ahead of consensus estimates and earnings per share surpassing Wall Street expectations, the analyst tells investors in a research note. The firm called the report a “good start to the year,” adding that it believes the sell-off is related to Q2 EMEA order shift, positioning into the print, and 2026 tariff commentary.